Table 2.
Clinicopathologic characteristics and chemotherapy of subgroups divided by type of surgery.
| Characteristics | BCS + Rad (n = 37) | Mastectomy (n = 46) | p-value | ||
|---|---|---|---|---|---|
| No | % | No | % | ||
| Age at diagnosis (years) | |||||
| Median | 58 | 57 | |||
| Range (IQR) | 48–66 | 41–67 | |||
| Gender | 0.125 | ||||
| Female | 37 | 100.00 | 42 | 91.30 | |
| Male | 0 | 0.00 | 4 | 8.70 | |
| Laterality | 0.840 | ||||
| Left | 20 | 54.05 | 27 | 58.70 | |
| Right | 17 | 45.95 | 19 | 41.30 | |
| Ethnicity | 0.330 | ||||
| White | 32 | 86.49 | 37 | 80.43 | |
| Black | 2 | 5.41 | 7 | 15.22 | |
| Other | 3 | 8.11 | 2 | 4.35 | |
| Pathologic tumor size | 0.052 | ||||
| pT1 | 29 | 78.38 | 25 | 54.35 | |
| pT2 | 6 | 16.22 | 18 | 39.13 | |
| pT3 | 2 | 5.41 | 3 | 6.52 | |
| Nodal status | 0.722 | ||||
| pN0 | 28 | 75.68 | 29 | 63.04 | |
| pN1 | 7 | 18.92 | 15 | 32.61 | |
| pN2 | 2 | 5.41 | 2 | 4.35 | |
| Nuclear grade | 0.527 | ||||
| I | 17 | 45.95 | 17 | 36.96 | |
| II | 17 | 45.95 | 22 | 47.83 | |
| III | 3 | 8.11 | 7 | 15.22 | |
| ER status | 0.729 | ||||
| Positive | 24 | 64.86 | 27 | 58.70 | |
| Negative | 13 | 35.14 | 19 | 41.30 | |
| PR status | 0.420 | ||||
| Positive | 17 | 45.95 | 16 | 34.78 | |
| Negative | 20 | 54.05 | 30 | 65.22 | |
| Chemotherapy | 0.998 | ||||
| Yes | 17 | 45.95 | 20 | 43.48 | |
| No/unknown | 20 | 54.05 | 26 | 56.52 | |
pT1 pathological tumor size ≤ 2 cm, pT2 2 cm < pathological tumor size ≤ 5 cm, pT3 pathological tumor size > 5 cm, pN0 negative regional lymph node, pN1, 1 to 3 regional lymph node metastasis, pN2 4 to 9 regional lymph node metastasis, Nuclear grade I well differentiation, Nuclear grade II moderate differentiation, Nuclear grade III poor differentiation, ER estrogen receptor, PR progesterone receptor, BCS breast conserving surgery.